REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
9.17
-0.03 (-0.33%)
Apr 25, 2025, 4:00 PM EDT - Market closed
REGENXBIO Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for REGENXBIO stock have an average target of 31.75, with a low estimate of 12 and a high estimate of 52. The average target predicts an increase of 246.24% from the current stock price of 9.17.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for REGENXBIO stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 3 | 4 | 3 |
| Buy | 7 | 7 | 7 | 7 | 4 | 4 |
| Hold | 1 | 1 | 1 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $14 → $12 | Hold | Maintains | $14 → $12 | +30.86% | Apr 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $34 | Strong Buy | Reiterates | $34 | +270.77% | Mar 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $34 | Strong Buy | Reiterates | $34 | +270.77% | Mar 20, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $52 | Strong Buy | Maintains | $52 | +467.07% | Mar 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $36 → $34 | Strong Buy | Maintains | $36 → $34 | +270.77% | Mar 17, 2025 |
Financial Forecast
Revenue This Year
320.93M
from 83.33M
Increased by 285.14%
Revenue Next Year
298.84M
from 320.93M
Decreased by -6.88%
EPS This Year
-0.50
from -4.59
EPS Next Year
-2.15
from -0.50
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 475.8M | 479.9M | 571.2M | ||
| Avg | 320.9M | 298.8M | 333.8M | ||
| Low | 78.4M | 78.7M | 214.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 471.0% | 49.5% | 91.1% | ||
| Avg | 285.1% | -6.9% | 11.7% | ||
| Low | -5.9% | -75.5% | -28.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.61 | 1.13 | 2.46 | ||
| Avg | -0.50 | -2.15 | -1.70 | ||
| Low | -4.70 | -5.50 | -4.02 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.